OPNT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OPNT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Opiant Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-1.93. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-6.57.
Opiant Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2022 was $-1.93. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-6.51.
Opiant Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2022 was $-1.93. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-6.57.
The historical data trend for Opiant Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opiant Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jul12 | Jul13 | Jul14 | Jul15 | Jul16 | Jul17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Earnings per Share (Diluted) | Get a 7-Day Free Trial | 2.94 | -7.10 | 2.17 | -0.44 | 0.51 |
Opiant Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Oct17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | 0.56 | 0.10 | -2.43 | -2.31 | -1.93 |
For the Biotechnology subindustry, Opiant Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Opiant Pharmaceuticals's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Opiant Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2021 is calculated as
Diluted Earnings Per Share (A: Dec. 2021 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (3.009 | - | 0) | / | 5.920 | |
= | 0.51 |
Opiant Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2022 is calculated as
Diluted Earnings Per Share (Q: Sep. 2022 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-9.917 | - | 0) | / | 5.138 | |
= | -1.93 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Opiant Pharmaceuticals (NAS:OPNT) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
David D O'toole | officer: Chief Financial Officer | 1640 MARENGO STREET, LOS ANGELES CA 90033 |
Ellison Mark Jason Heath | other: UK Managing Director | C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401 |
Roger Crystal | director, 10 percent owner, officer: Chief Executive Officer | 445 PARK AVE, 10TH FL., NEW YORK NY 10022 |
Phil Skolnick | officer: Chief Scientific Officer | C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601 |
Brian Gorman | other: General Counsel | 233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401 |
Matthew R. Ruth | officer: Chief Commercial Officer | 233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401 |
Michael Sinclair | director, 10 percent owner, officer: Executive Chairman | 86 GLOUCESTER PLACE, LONDON XX W1U6HP |
Craig A Collard | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Ann L. Macdougall | director | C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401 |
Thomas T. Thomas | director | C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401 |
Masuoka K. Lorianne | director | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Gabrielle Alison Silver | director | C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401 |
Rahsaan Thompson | other: General Counsel | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Richard J Daly | director | 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134 |
From GuruFocus
By PRNewswire PRNewswire • 11-14-2022
By PurpleRose PurpleRose • 08-22-2022
By Business Wire Business Wire • 01-07-2023
By PRNewswire PRNewswire • 12-01-2022
By Value_Insider Value_Insider • 10-27-2022
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 11-22-2022
By Business Wire Business Wire • 11-15-2022
By Value_Insider Value_Insider • 11-15-2022
By Stock market mentor Stock market mentor • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.